Controlled Evaluation of the Clinical Effect of Asthremedin^® on Nasal Allergy

Abstract

A multicenter controlled trial was performed to evaluate the effectiveness and the usefulness of Asthremedin in 152 patients with nasal allergy.
The patients of the Asthremedin group received Asthremedin intradermal injection once a week for four weeks in addition to the conventional treatment. The patients of the control group received only the conventional treatment.
In the final global improvement rating, the rate of improvement was 73.2% for the Asthremedin group and 45.0% for the control group. There was a statistically significant difference between the Asthremedin group and the control group in final global improvement and final improvement of each symptom.
Side effects were observed in three patients. They were local and minimal symptoms.
The mechanism of action of Asthremedin was attributed to its effect of reducing histamine sensitivity of the nasal mucous membrane.